PTC Q3 Revenue $358M, Full-Year Revenue Guidance Raised to $1.29-$1.32B
PTCT is trading near its 52-week low of $58.8 (2.0% above the low).
Summary
PTC reported Q3 2026 revenue of $358 million and raised full-year product revenue guidance to $960-$990 million, while a $111 million ST-920 IPR&D charge pushed the quarter to a $51.7 million net loss.
Key Events · Earnings and Guidance · PTCT
-
Q3 Revenue $358M, Sephience $182M
Total revenue was $357.8 million versus $211.0 million a year ago; Sephience contributed $181.9 million, up 20% from Q2 2026, with over 2,000 active patients worldwide.
-
Full-Year Guidance Raised
Total 2026 revenue guidance increased to $1.29-$1.32 billion and product revenue guidance rose to $960-$990 million from $850-$950 million; non-GAAP R&D and SG&A guidance held at $680-$720 million.
-
Net Loss on ST-920 Charge
Net loss was $51.7 million, or $0.62 per share, including a $111.0 million acquired IPR&D charge for ST-920 and a $19.3 million loss on debt extinguishment.
-
Cash $2.13B, Breakeven Targeted
Cash, cash equivalents and marketable securities were $2,127.9 million at September 30, 2026, up from $1,945.4 million at December 31, 2025; management reiterated 2026 cash flow breakeven.
Analysis · PTCT · Life Sciences
Revenue of $357.8 million beat the year-ago $211.0 million, powered by Sephience's first full launch year, and management raised full-year product revenue guidance to $960-$990 million from $850-$950 million. The quarter still printed a $51.7 million net loss, driven largely by the $111.0 million upfront ST-920 IPR&D charge and a $19.3 million debt extinguishment loss, so the headline red ink overstates operating deterioration. With $2.13 billion of cash and management reiterating 2026 cash flow breakeven, the raised guidance is the part that matters for the thesis.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PTCT was trading at $60.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $58.80 to $90.87. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.